Your Drug Needs a Device Patent to Survive: The MedTech Crossover Strategy

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

How combination patent architecture protects pharmaceutical revenue after composition-of-matter expiry — and what the post-Teva v. Amneal landscape means for IP teams building exclusivity today

Why the Drug-Device Boundary No Longer Matters the Way It Used To

For most of the twentieth century, a pharmaceutical company’s IP department and its device engineering team occupied separate floors, separate budgets, and sometimes separate buildings. The drug was the asset. The device was the packaging. If your molecule was patented, you were protected. If the molecule’s patent expired, you lost the market.

That mental model has been obsolete for at least a decade, and its replacement is now one of the most contested territories in pharmaceutical intellectual property law. The drug-device combination patent — a patent that claims not just the active pharmaceutical ingredient (API) but the mechanism that delivers it, the engineering that controls its release, or the physical system through which it interfaces with human biology — is no longer a secondary line of defense. For a growing cohort of high-revenue branded products, it is the primary one.

The U.S. market for drug-device combination products was valued at over $46 billion in 2023 and is forecast to exceed $78 billion by 2030.^[1] That growth is not driven by incremental product improvements. It reflects a structural shift: the most commercially important therapies in oncology, immunology, diabetes, and rare disease increasingly cannot be administered without a proprietary delivery system. The device is inseparable from the drug. And where inseparability exists, IP strategy follows.

But the rules changed dramatically in December 2024, when the U.S. Court of Appeals for the Federal Circuit issued its opinion in Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC. The court’s holding — that a patent must claim at least the active ingredient to qualify for listing in the FDA’s Orange Book — drew a bright line through what had previously been a gray area. The consequences have rippled through inhaler, autoinjector, and prefilled syringe markets from the moment the stay lifted.

This article works through the full architecture of drug-device combination patent strategy: why it matters commercially, how it is built legally, where it is being challenged regulatorily and through litigation, and what a defensible post-Teva v. Amneal combination patent portfolio looks like for IP teams working on the most commercially consequential products of the next decade.

What Is a Drug-Device Combination Patent? Definitions and Scope

Short answer: A drug-device combination patent is a patent that claims one or more elements of a product that contains both an active pharmaceutical ingredient and a delivery or administration device — typically an autoinjector, inhaler, prefilled syringe, infusion pump, implantable system, or connected sensor. These patents can claim the device alone, the device in combination with specific drug characteristics, or a system that integrates drug and hardware into a single therapeutic unit.

The Four Types of Drug-Device Combination Patents

Before getting into strategy, the taxonomy matters because different patent types face different legal treatment, different Orange Book eligibility rules, and different challenge vectors:

• API-reciting device patents: Claims that describe a device element but also recite the active ingredient by name or by a defined functional characteristic. These are eligible for Orange Book listing under the post-Teva v. Amneal standard and carry the full weight of Hatch-Waxman protection including the 30-month stay.
• Device-only patents (non-listable): Claims covering the mechanical, electronic, or structural features of a delivery system without reciting the API. Valid and enforceable, but no longer Orange Book listable. Generic or biosimilar challengers can seek FDA approval without triggering an automatic stay on these patents. Infringement suits are still possible, but the procedural leverage differs substantially.
• System-of-use patents: Claims covering the combination of drug and device in the context of a specific therapeutic use, dosing regimen, or patient population. These include method-of-treatment claims that reference both the drug and the device administration system. They are often the most durable layer of exclusivity because they are the hardest to design around without changing the approved clinical workflow.
• Software and connectivity patents: Claims covering sensor systems, dose-tracking algorithms, closed-loop control logic, or data interfaces that operate in combination with the drug product. These represent the newest and fastest-growing layer of combination product IP, and their eligibility under both patent law and FDA frameworks is still being defined.

How FDA Defines Combination Products: 21 CFR 3.2(e) and the PMOA Rule

The FDA’s regulatory definition of a combination product under 21 C.F.R. § 3.2(e) covers four configurations: a single-entity product physically combining drug and device; co-packaged products; separately packaged but cross-labeled products; and investigational products intended for use only with a specified device or drug. The key regulatory determination — which FDA center takes the lead on approval review — turns on the Primary Mode of Action, or PMOA.

Under 21 C.F.R. § 3.2(m), the PMOA is the single mode of action expected to make the greatest contribution to the overall intended therapeutic effects of the combination product. If the drug constituent provides the PMOA, the Center for Drug Evaluation and Research (CDER) leads. If the device provides it, the Center for Devices and Radiological Health (CDRH) leads. For biologics, the Center for Biological Evaluation and Research (CBER) may lead.^[2]

This PMOA determination has direct patent strategy implications. It dictates which regulatory pathway governs approval, which exclusivity protections apply, and — as Teva v. Amneal confirmed — which patents are eligible for Orange Book listing. A drug-PMOA combination product approved via NDA brings the full Hatch-Waxman framework. A device-PMOA product approved via PMA does not.

Orange Book vs. Purple Book: Which Patents End Up Where

The FDA’s Orange Book lists patents for drug products approved under NDAs and 505(b)(2) applications. The Purple Book covers biological products approved under BLAs. The rules for listing are different, and the generic/biosimilar challenge mechanics are different.

For the Orange Book, a patent must claim the drug or a method of using the drug. Post-Teva v. Amneal, that means it must claim at least the API. A patent covering only a device component cannot be listed regardless of whether the product was approved as a combination product via NDA. For the Purple Book, biosimilar patent litigation proceeds through the BPCIA’s patent dance framework rather than Hatch-Waxman’s automatic-stay mechanism, which changes the leverage calculus substantially.

The Commercial Rationale: Why Device Patents Are Now Central to Revenue Defense

The case for building device patents into a pharmaceutical IP strategy rests on a straightforward commercial reality: composition-of-matter (CoM) patents expire. When they do, the drug’s revenue base faces generic or biosimilar erosion that can remove 80 to 90 percent of branded volume within two years of first generic entry. Device patents, filed later in a product’s lifecycle and covering continuous engineering improvements, extend the protection horizon beyond CoM expiration — sometimes by nearly a decade.

In a 2026 JAMA Health Forum cohort study of 331 drug-device combinations approved by the FDA from 1986 to 2023, medical device patents extended periods of market exclusivity for 180 products (54.4%) by a median of 7.5 years, with most device patents failing to mention the active pharmaceutical ingredients in their claims.^[3]Teng TW et al., “Tertiary Patents on Drugs Approved by the FDA,” JAMA Health Forum, January 2026

That figure — 7.5 years of median exclusivity extension — represents, for a $5 billion annual revenue product, a potential $37.5 billion in additional protected sales. The device patent is not a defensive afterthought. It is the revenue retention mechanism.

The Humira Blueprint: 132 Patents, a Citrate-Free Formulation, and a 29-Gauge Needle

AbbVie’s management of adalimumab (Humira) is the canonical case study. By the time biosimilar companies began filing applications in the early 2010s, AbbVie had built a portfolio of over 130 patents, the vast majority filed after Humira was already approved and generating commercial revenues.^[4] These secondary patents covered formulation changes, including citrate-free and high-concentration versions, and delivery device innovations tied to the autoinjector pen, specific injection schedules for each indication, and manufacturing process improvements.

In 2016, AbbVie introduced a high-concentration citrate-free formulation that used a 29-gauge needle instead of a 27-gauge needle, reducing injection volume from 0.8 ml to 0.4 ml. This change reduced injection site reactions — previously reported in 12.9% of patients — and generated fresh patentable subject matter on both the formulation and the delivery device.^[4] From a purely clinical perspective, it was a genuine improvement. From an IP strategy perspective, it restarted part of the exclusivity clock.

The strategy produced exactly the commercial outcome AbbVie designed. Biosimilar companies approved for adalimumab — Amgen’s Amjevita, Sandoz’s Hyrimoz, Boehringer Ingelheim’s Cyltezo, and several others — each settled with AbbVie on licensed entry dates beginning in January 2023. Delayed biosimilar entry for Humira cost the U.S. healthcare system an estimated $7.6 billion in excess spending.^[4] AbbVie extracted roughly two full decades of U.S. market dominance for a molecule whose core composition-of-matter patent had technically expired years earlier.

EpiPen Device Patents and the $600 Two-Pack: A Cautionary Analogy

Not every device patent story ends cleanly. Mylan’s management of the epinephrine autoinjector (EpiPen) became a public policy flashpoint when device and manufacturing patents on the injector system, not the epinephrine API itself, enabled pricing latitude that drove the cost of a two-pack from roughly $100 in 2008 to approximately $600 by 2016.^[5] In January 2025, Mylan reached a $73.5 million settlement with KPH Healthcare Services following accusations that it conspired with Pfizer and Teva to delay the release of generic versions by maintaining a device patent-backed monopoly.^[5]

The EpiPen case illustrates both the commercial power and the reputational and legal risk of device-based exclusivity. It also demonstrates the enforcement gradient that regulators and plaintiffs will use when device patents appear to serve primarily as generic barriers rather than genuine clinical innovations.

GLP-1 Injector Pens: The Next Battleground

The most commercially significant current application of drug-device patent strategy involves GLP-1 receptor agonists. Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro and Zepbound (tirzepatide) are administered via proprietary injector pens that carry their own patent portfolios. The FTC’s 2024 crackdown on Orange Book patent listings specifically targeted pen-injector patents for Ozempic, Victoza, and Saxenda.^[6]

In response to the FTC’s challenges and the Federal Circuit’s December 2024 ruling, Novo Nordisk delisted all FTC-challenged patents on the devices that deliver Ozempic, Victoza, and Saxenda.^[7] The underlying drug and method-of-use patents remain. But the pen-only patents are gone from the Orange Book. For a company managing approximately $25 billion in annual GLP-1 revenue, this is a material change in exclusivity architecture — one that IP teams at competing companies are dissecting in detail right now.

The Orange Book Listing Crisis: What Teva v. Amneal Changed

Background: How Orange Book Listing Works and Why It Matters

Short answer: When a drug manufacturer receives FDA approval via an NDA, it must list all patents covering the approved drug in the Orange Book. When a generic company files an Abbreviated New Drug Application (ANDA) challenging any of those patents, the brand manufacturer can sue for infringement, triggering an automatic 30-month stay that prevents FDA from approving the generic while litigation proceeds. The stay is the mechanism. Orange Book listing is how you activate it.

The 30-month stay is one of the most valuable procedural rights in pharmaceutical law. It costs nothing to trigger — only a timely lawsuit — and it can delay a generic product’s market entry by two and a half years regardless of the ultimate merits of the patent. For a drug generating $3 billion annually, a 30-month stay is worth roughly $7.5 billion in protected revenue. This is why every patent that might plausibly qualify for listing gets listed. Or at least, why it used to.

Teva v. Amneal: The Ruling That Redrew the Map

Teva holds an NDA for ProAir HFA Inhalation Aerosol, a metered-dose inhaler delivering albuterol sulfate for asthma. Teva listed nine non-expired patents in the Orange Book for this product, including five that covered only the mechanical device components of the inhaler — specifically the dose counter and canister features — without reciting albuterol sulfate or any API in their claims.^[8]

When Amneal Pharmaceuticals filed an ANDA seeking generic approval and provided paragraph IV certifications against the listed patents, Teva sued for infringement, triggering the 30-month stay. Amneal counterclaimed seeking delisting of the device-only patents, arguing they did not “claim the drug” as required by 21 U.S.C. § 355(b)(1)(A)(viii). The FTC filed an amicus brief in March 2024 in support of Amneal’s position.

In June 2024, the District Court for the District of New Jersey, Judge Stanley Chesler, granted Amneal’s motion and ordered Teva to delist the five challenged patents. Teva appealed. On December 20, 2024, the Federal Circuit affirmed:

To list a patent in the Orange Book, that patent must, among other things, claim the drug for which the applicant submitted the application and for which the application was approved. And to claim that drug, the patent must claim at least the active ingredient.Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, Fed. Cir. Case No. 2024-1936 (Dec. 20, 2024)

The court was explicit that the NDA approval pathway does not convert device components into “drugs” for listing purposes. Teva argued that because ProAir HFA was approved as a combination product via NDA — meaning the drug mode of action predominated — every component of the product qualified as part of the “drug.” The Federal Circuit rejected that argument, holding that the combination product’s NDA approval means only that the drug’s mode of action predominated, not that the physical device hardware became a drug.^[9]

The 30-Month Stay — Lost, Not Gone

A critical nuance that patent counsel and generics strategy teams need to internalize: delisting a patent from the Orange Book does not invalidate the patent. Teva’s device patents remain valid and enforceable. What Teva lost was the 30-month stay on FDA approval of Amneal’s generic. Teva can still sue Amneal for device patent infringement in federal district court. But the FDA was free to approve Amneal’s generic albuterol aerosol while that litigation proceeds, and Amneal can launch “at risk.”^[10]

In December 2025, largely as a result of the cleared patent pathway, the FDA approved Amneal’s generic albuterol sulfate inhalation aerosol.^[10] That approval arrived without the benefit of any 30-month stay from the device patents. The commercial consequence — immediate generic competition for ProAir HFA — confirms that the Federal Circuit’s ruling carries real economic force, not just doctrinal significance.

FTC Enforcement: 300+ Listings Challenged Across Inhalers, Autoinjectors, and GLP-1 Pens

The Federal Circuit’s ruling validated a campaign the FTC had been running since late 2023. In November 2023 and April 2024, the FTC challenged over 300 patent listings across multiple drug-device combination products, including inhalers, multidose eyedrop bottles, and autoinjectors.^[6] The initial campaign led to the delisting of patents for 22 brand-name products. In May 2025, the FTC renewed those challenges, issuing warning letters to five companies regarding over 200 patents that remained listed despite prior FTC objections.^[11]

The FTC targeted specific inhalers marketed by Teva under its Respiclick, Digihaler, and Redihaler platforms, with approximately 60 patents challenged across five brands. GSK’s Anoro Ellipta and Trelegy Ellipta faced specific FTC challenges. Boehringer Ingelheim’s Combivent Respimat and Spiriva Respimat faced scrutiny over Respimat inhaler patents. AstraZeneca, AbbVie, Novartis, Covis Pharmaceuticals, and Amphastar also had patents targeted.^[11]

Importantly, FTC enforcement under the current Republican administration — which critics had expected to pull back from this front — has continued. The May 2025 warning letters were issued under the Trump FTC, demonstrating that the Orange Book listing issue has become institutionally embedded in regulatory enforcement regardless of which party controls the commission.

The Antitrust Dimension: When Improper Listing Becomes Walker Process Liability

Orange Book listing carries antitrust risk that most brand-side IP teams underweight. Amneal’s counterclaims in Teva v. Amneal included antitrust allegations, arguing that the listing of device-only patents wrongfully delayed ANDA approval and caused anticompetitive harm. The district court denied Teva’s motion to dismiss those antitrust claims.^[12]

The antitrust theory rests on Walker Process doctrine and sham litigation principles. A patent holder that knowingly lists patents that fail the listing statute — and then uses those listings to trigger automatic stays that delay generic entry — may face Sherman Act liability. The FTC’s amicus brief explicitly characterized improper listings as “sham patents” that “illegally delay generic competition.”^[12] If courts accept that framing, the damages exposure from improper device patent listings dwarfs the cost of any audit to identify and delist non-qualifying patents.

Building a Defensible Drug-Device Combination Patent Portfolio Post-2024

The API-Recitation Requirement: How to Draft Claims That Qualify for Orange Book Listing

Short answer: For a device-related claim to qualify for Orange Book listing after Teva v. Amneal, it must include at least one claim element that specifically recites the active pharmaceutical ingredient. A claim covering only the mechanical, electronic, or structural features of the delivery system without naming the API or its functional equivalent will not meet the listing standard.

The practical implication for patent drafting is that device patent applications for combination products must include claims that integrate API reference from the first filing. This is a departure from the traditional device patent workflow, which focused exclusively on mechanical novelty and left API chemistry to separate pharmaceutical filings.

Post-Teva v. Amneal, the claim architecture for a listable combination product patent needs at minimum one independent claim structured roughly as: “A drug delivery system comprising [specific device elements] for administering [named API] to a patient.” Dependent claims can then elaborate on device specifics without repeating the API reference. The API reference in the independent claim is the hook that makes the patent Orange Book listable.

Claims That Survived vs. Claims That Failed: A Comparative Framework

Claim Type	Recites API?	Orange Book Eligible?	Example
Device-only (dose counter)	No	No (post-Teva v. Amneal)	Teva’s ProAir HFA dose counter claims
Device + API reference	Yes	Yes	“Inhaler for delivering albuterol sulfate comprising…”
Method of use (device + drug)	Yes (implicitly via use)	Yes	“Method of treating asthma by administering albuterol via [device]…”
Formulation + device	Yes	Yes	“Pharmaceutical composition comprising [API] + [excipients] in [device form]…”
Software/sensor alone	No	No	Dose-tracking algorithm without API reference
System: drug + device + method	Yes	Yes	Closed-loop insulin delivery claiming specific insulin + sensor + control logic

Prosecution Strategy: Filing a Parallel Device Patent Family That Integrates API Claims

The practical recommendation from the post-Teva v. Amneal decisions is to file device patent applications as continuation-in-part (CIP) applications from parent pharmaceutical filings, or as independent applications with explicit API recitation in at least the primary independent claim. This creates a family structure where the Orange Book-listable claims and the device-only claims coexist in the same patent, providing both Hatch-Waxman coverage and enforceable mechanical claims.

Some counsel have also recommended reissue proceedings for existing device patents that lack API recitation. Under 35 U.S.C. § 251, a patent that is “wholly or partly inoperative or invalid” due to a defect in the specification or claims can be reissued. Whether a patent that currently lacks API claims can be reissued to add such claims without adding new matter is a fact-specific question, but the Finnegan analysis published in May 2025 identifies reissue as a viable mechanism where claim scope can be preserved while adding API-reciting claims.^[13]

The Combination Product Patent Stack: Building the Full IP Architecture

A defensible drug-device combination patent portfolio does not rest on a single patent. It is an architecture with multiple layers, each serving a different legal function and each defended through a different mechanism. DrugPatentWatch’s analysis of pharmaceutical post-expiration strategies identifies four sequential layers that work together:^[14]

The first layer is the core pharmaceutical estate: composition-of-matter on the API and its clinically relevant forms (polymorphs, salts, esters), formulation patents on the specific pharmaceutical composition including excipients, stabilizers, and pH modifiers that affect bioavailability or shelf life, and synthesis or process patents. For a biologic, this layer includes antibody sequence claims, expression system claims, and purification process claims.

The second layer is the device integration layer: patents on the delivery system that include API-reciting claims sufficient for Orange Book listing. This layer must be drafted with Teva v. Amneal compliance as a baseline requirement, not an afterthought.

The third layer is the clinical use layer: method-of-treatment patents covering specific dosing regimens, patient selection criteria, titration protocols, and combination-use scenarios that reference both the drug and the device. These claims often survive the longest because they cannot be designed around without changing the approved clinical practice.

The fourth and newest layer is the connected device and software layer: claims covering sensor-integrated dosing systems, patient adherence monitoring, closed-loop control algorithms, and interoperability standards for device-to-health record data transfer. This layer is building rapidly in diabetes (closed-loop insulin delivery), respiratory disease (connected inhalers), and oncology (implantable drug delivery systems).

Why Device Patents Alone — Without API Recitation — Still Have Strategic Value Post-Teva

Even though device-only patents cannot be listed in the Orange Book, they retain substantial value. They are enforceable against generic and biosimilar manufacturers who copy the device system, against contract device manufacturers serving the generic supply chain, and against competitor branded products that infringe the mechanical innovations. The loss of Orange Book listing removes the procedural 30-month stay, but the underlying patent right is intact.

For biosimilar competition governed by the Purple Book rather than the Orange Book — which covers biologics like adalimumab, tocilizumab, or dupilumab — device patents operate differently. BPCIA litigation does not use the same automatic-stay mechanism. Device patent enforcement in the biosimilar context typically occurs through pre-launch litigation in federal district court, which may or may not obtain a preliminary injunction depending on the facts.

Case Studies: How Device Patents Changed the LOE Timelines for Six Major Products

Advair Diskus and the Inhaler Patent Playbook: GSK’s Fluticasone-Salmeterol Exclusivity Extensions

GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) is one of the clearest historical examples of device patent-driven exclusivity extension. The core API patents on fluticasone propionate and salmeterol xinafoate expired years before meaningful generic competition arrived for the combination inhaler. GSK held numerous patents on the Diskus dry-powder inhaler mechanism itself, its internal geometry, foil packaging, and dose-counting system. These device patents, combined with the complexity of demonstrating pharmaceutical equivalence for an orally inhaled product, delayed generic entry into the U.S. market by approximately a decade beyond the API patent expiration.

FDA’s approach to inhaled product bioequivalence — which requires complex pharmacokinetic studies, in vitro testing, formulation matching, and device comparability — creates a regulatory barrier that device patents reinforce. The device patent and the regulatory science work together. GSK’s Anoro Ellipta and Trelegy Ellipta products followed a similar architectural model with their Ellipta inhaler device. Both were explicitly targeted by the FTC’s April 2024 Orange Book listing challenge.^[11]

AbbVie Humira: The Autoinjector Patent as Biosimilar Settlement Lever

The Humira case is discussed above, but one aspect deserves separate treatment: the role of device patents in settlement negotiations. When a biosimilar manufacturer faces a patent thicket that includes autoinjector patents, formulation patents, and method-of-use patents, the economics of litigation versus settlement shift decisively toward settlement. Clearing the autoinjector patents alone requires separate validity challenges and infringement analyses that multiply the legal spend and timeline of any invalidation campaign.

AbbVie’s autoinjector patent estate effectively served as a settlement pressure device. Biosimilar companies that might have challenged the core adalimumab CoM patents — had they been the only barrier — faced a portfolio of 130+ patents that made the litigation cost of full challenge prohibitive. Each settlement specified a licensed U.S. entry date, with royalty terms in some agreements. The autoinjector patents contributed meaningfully to the leverage that produced settlement terms favorable enough to sustain Humira’s U.S. revenue through 2023.^[4]

Entresto (Sacubitril/Valsartan): Formulation-Device Integration and the January 2025 Federal Circuit Win

Novartis’s Entresto (sacubitril/valsartan) for heart failure generated approximately $7.8 billion in annual revenue in 2024 with loss of exclusivity exposure in mid-2025.^[15] The combination’s patent thicket includes composition-of-matter protection on sacubitril-valsartan as a molecular complex, formulation patents on the specific tablet architecture, and method-of-use patents covering the validated heart failure dosing regimen.

In January 2025, the Federal Circuit rejected generic manufacturers’ written description challenges to the foundational Entresto patent, holding that the specification adequately described the claimed combination even though the specific sacubitril-valsartan complex was not known when the patent was filed.^[16] This ruling extended Entresto’s core patent protection and gives Novartis additional time to build out device and formulation-based exclusivity for any follow-on dosage forms or delivery systems.

Spiriva Respimat and Combivent Respimat: Boehringer Ingelheim’s Respimat Device Patents Under Scrutiny

Boehringer Ingelheim’s Respimat inhaler — used for Spiriva (tiotropium) for COPD and Combivent Respimat (ipratropium/albuterol) — became a specific target in discussions about device patent strategy and generic delay. Device patents on the Respimat’s soft-mist delivery mechanism, its unique valve system that creates a slow-moving aerosol without propellant, were identified as a source of exclusivity extension beyond the tiotropium API patent expiration.^[17] The Respimat mechanism is genuinely innovative and clinically differentiated. Its patents covering the actuator, valve geometry, and aerosol particle size characteristics represent real engineering investment. But their interaction with the Orange Book and the 30-month stay raised the same policy concerns as inhaler dose counters that add no clinical value.

Ozempic and Wegovy: Novo Nordisk’s Injector Pen Strategy Under FTC Pressure

Novo Nordisk’s FlexPen and FlexTouch injector systems for semaglutide represent a more current example of device patent strategy being unwound in real time. The FTC challenged device patents on pens used to administer Ozempic, Victoza, and Saxenda, and Novo Nordisk subsequently delisted those FTC-challenged patents from the Orange Book.^[7] The remaining semaglutide Orange Book listings cover the drug and method-of-use patents — which remain substantial — but the pen-device-only layer is gone.

Novo Nordisk sued nine generic firms over semaglutide in 2022, settling on terms that delayed generic entry, and filed new suits in 2024.^[18] The semaglutide NCE exclusivity expired, but new patient population exclusivity for weight management ran until December 2025. Tirzepatide’s NCE exclusivity runs to May 2027. In both cases, the relevant exclusivity is now anchored in drug and method patents, not device listings — a direct consequence of the FTC enforcement campaign and the Federal Circuit’s ruling.

Closed-Loop Insulin Delivery: The Medtronic and Tandem Patent Architectures

The most sophisticated current examples of drug-device patent integration are in closed-loop insulin delivery. Medtronic’s MiniMed systems and Tandem Diabetes Care’s Control-IQ technology each combine an insulin pump, a continuous glucose monitor, and an algorithm that adjusts insulin delivery automatically. The patent portfolios for these systems span device claims on pump mechanics, sensor chemistry, software claims on control algorithms, and method-of-treatment claims on the combined glycemic management approach.

For Medtronic, the insulin itself is not covered by the device patents — insulin analogs like lispro (Humalog) or aspart (NovoLog) have their own separate IP estates controlled by Eli Lilly and Novo Nordisk. What Medtronic and Tandem own is the delivery architecture. In this context, the API-recitation requirement of Teva v. Amneal is less directly applicable because the insulin used in these systems is separately approved and separately purchased. But the strategic question of how device IP interacts with drug IP remains central to the commercial competition between closed-loop systems.

Paragraph IV Challenges and Litigation Strategy for Combination Products

How Paragraph IV Certification Works for Drug-Device Products

When a generic manufacturer files an ANDA for a drug-device combination product, it must certify with respect to each Orange Book-listed patent. Under paragraph IV of 21 U.S.C. § 355(j)(2)(A)(vii), the generic certifies that the patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing a paragraph IV certification is legally treated as an act of patent infringement, which triggers the brand manufacturer’s right to sue within 45 days and activate the 30-month stay.

For combination products, the infringement analysis must cover both drug and device aspects. A generic inhaler may use a different dose counter mechanism (non-infringement of device claims) while delivering the same API at the same particle size distribution (potential infringement of formulation or method claims). The paragraph IV notice letter must address all listed patents. If only some claims are contested, the generic’s exposure is shaped by which patents it can credibly challenge.

What a Paragraph IV Certification Against a Combination Product Actually Contains

Paragraph IV notices for combination products are characteristically longer and more technical than those for simple tablet or capsule generics. The notice letter must provide specific factual and legal bases for why each listed patent is invalid or not infringed. For inhaler device patents, the analysis typically includes detailed reverse-engineering of the brand device to identify mechanical differences that support non-infringement, prior art searches for the device mechanisms at issue, and construction of each claim element in light of the specification.

Given the Federal Circuit’s ruling, paragraph IV certifications for products that still carry device-only listings should include a delisting counterclaim — seeking court-ordered removal of any patents that fail the API-recitation standard. This is exactly what Amneal did successfully in the Teva v. Amneal proceeding, and the precedent makes it a standard move in the post-2024 litigation playbook for any ANDA filer whose target product carries device-only Orange Book listings.

Serial Patent Litigation as a Delay Strategy: The Mirabegron Pattern Applied to Device Claims

A documented tactic in pharmaceutical patent litigation involves serial litigation campaigns where brand manufacturers file successive lawsuits based on continuation patents that recycle substantially similar claims in new applications after the original litigation concludes. In the case of Astellas’s mirabegron (Myrbetriq), after an initial Hatch-Waxman case settled in 2020 with generic entry expected in 2024, Astellas pursued four additional lawsuits, each built on continuation patents with narrowly varied claim language.^[19] These tactics delayed broad competition, leaving only two firms to launch in 2024 under the threat of damages exposure.

For drug-device combination products, continuation strategies can be applied to device patent families to generate successive litigation fronts even after early device patents expire or are invalidated. Each new continuation patent triggers a fresh paragraph IV obligation from generic filers, a new potential lawsuit, and potentially a new 30-month stay if the continuation includes an API-reciting claim that qualifies for Orange Book listing.

The post-Teva v. Amneal constraint is that each continuation in this device family must include API-reciting claims in at least one independent claim to preserve Orange Book eligibility. This is not technically difficult, but it requires drafting discipline that many device patent prosecution teams — trained in traditional device patent practice without pharmaceutical IP overlay — do not automatically apply.

The 180-Day Generic Exclusivity Incentive for First Filers Challenging Device Patents

The first generic company to file a paragraph IV certification against all Orange Book patents for a given drug product typically qualifies for 180 days of generic market exclusivity before other ANDAs for the same product receive approval. For a high-revenue drug-device product, this 180-day exclusivity can be worth hundreds of millions of dollars and effectively transforms the paragraph IV challenge into a financial race as much as a scientific one.

The FTC’s delisting campaign changes the first-filer calculus for combination products. If device-only patents are delisted before a generic company files its ANDA, the generic faces fewer patents to certify against, fewer potential lawsuits, and a faster path to the 180-day exclusivity window. In effect, the FTC’s enforcement actions accelerated the competitive opportunity for first-filer generics in inhaler and autoinjector markets by reducing the patent barrier they needed to traverse.

The Purple Book Parallel: Device Patents in Biosimilar Competition Under BPCIA

How the BPCIA Patent Dance Handles Device Patents Differently

Biological products approved under BLAs are listed in the Purple Book, not the Orange Book, and biosimilar competition proceeds under the Biologics Price Competition and Innovation Act (BPCIA) framework rather than Hatch-Waxman. The BPCIA provides 12 years of exclusivity from BLA approval, during which no biosimilar can be approved. Patent disputes proceed through a multi-step “patent dance” framework rather than the automatic-stay mechanism of Hatch-Waxman.

Device patents for biologics — autoinjectors, prefilled syringes, on-body injectors — are not subject to Orange Book listing at all, because the Purple Book does not use the same listing-and-certification system. Enforcement of device patents against biosimilar manufacturers therefore requires traditional district court litigation, with no automatic stay. The brand manufacturer can seek a preliminary injunction, but must meet the standard four-factor test, including demonstration of irreparable harm, rather than receiving an automatic procedural stay.

Dupixent (Dupilumab) Device Strategy: Prefilled Syringe and On-Body Injector Patents

Regeneron and Sanofi’s Dupixent (dupilumab) for atopic dermatitis, asthma, and other type 2 inflammatory conditions generated global sales of $7.72 billion in 2022, with projections exceeding $11 billion by 2025.^[20] Dupixent is administered via prefilled syringe and, for some patients, a prefilled pen. The device patents for Dupixent’s delivery system exist and are being built out, but because Dupixent is a biologic approved under a BLA, they are not Orange Book issues. They are BPCIA issues.

As biosimilar entrants begin their BPCIA patent dance for dupilumab, device patents covering the prefilled syringe presentation and the pen delivery system will be among the disputed patents exchanged in the dance. Unlike the inhaler or autoinjector device-only patents that failed in Teva v. Amneal, BPCIA device patent disputes play out under different rules where the API-recitation requirement for Orange Book listing does not apply. The commercial question is whether device patents can be used to obtain preliminary injunctions that functionally replicate the competitive protection the 30-month stay provides in the Hatch-Waxman context.

Keytruda’s Patent Cliff and Device IP: Merck’s PD-1 Exclusivity Strategy

Merck’s pembrolizumab (Keytruda), the world’s top-selling drug with 2024 sales of approximately $29.5 billion, is facing a primary U.S. patent expiration around 2028.^[15] Keytruda is an intravenous biologic administered through hospital infusion systems — a delivery context that generates less commercially significant device patent opportunity than autoinjectors or inhalers. However, Merck is actively pursuing formulation work on subcutaneous pembrolizumab delivery — specifically a co-formulation with hyaluronidase, similar to the approach J&J used for subcutaneous rituximab and Roche for subcutaneous trastuzumab.

A subcutaneous pembrolizumab product would involve a prefilled device component — a syringe or autoinjector that co-packages the drug with the enzyme — and could generate both formulation and device patent protection. If approved and commercially adopted before the IV formulation’s primary exclusivity expires, a subcutaneous presentation with fresh IP can serve as a bridging product that maintains market share through the transition to the biosimilar era.

Regulatory Exclusivity vs. Patent Protection: How They Interact for Combination Products

FDA Exclusivity for Combination Products: NCE, NME, 3-Year, and Orphan

FDA regulatory exclusivity and patent protection are legally distinct systems that work in parallel. A drug-device combination product can receive multiple exclusivity grants depending on its composition and the nature of its NDA. New Chemical Entity (NCE) exclusivity provides five years of protection during which the FDA cannot accept an ANDA for the reference product. The three-year exclusivity provision applies to products where new clinical investigations were essential to approval — often the basis for new delivery system approvals when a new device is combined with an existing drug.

The interaction matters strategically because exclusivity periods and patent terms can overlap, extend sequentially, or leave gaps. A combination product that receives three-year exclusivity for a new device presentation of an existing drug has FDA-backed market protection for that period entirely independent of any patent. For the three years of exclusivity, no generic can receive ANDA approval even if all relevant patents were invalidated. After exclusivity expires, any remaining patents govern the competitive timeline.

Key FDA Exclusivity Types and Their Relevance to Drug-Device Combinations

Exclusivity Type	Duration	Applicability to Device Combinations	Can Block Generic?
NCE (New Chemical Entity)	5 years	Only if API is new chemical entity	Yes — FDA cannot even accept ANDA
3-Year Clinical Investigation	3 years	Available for new device presentations of existing drugs if new clinical data submitted	Yes — for specific approved change only
Orphan Drug	7 years	Available if combination product treats rare disease	Yes — prevents approval of same drug for same indication
Pediatric	6 months (extension)	Attaches to all existing exclusivities and patents if pediatric study completed	Yes — extends all protections by 6 months
BPCIA (Biologic)	12 years from BLA approval	Applies to biologic drug component; device patents governed separately	Yes — no biosimilar approval for 12 years

Patent Term Extension for Drug-Device Products: Which Patent Gets Extended?

Under 35 U.S.C. § 156, a patent that claims a drug product, method of using a drug, or a method of manufacturing a drug may receive a patent term extension (PTE) to compensate for time lost during FDA regulatory review. Only one patent per approved NDA or BLA can receive PTE, and the extension cannot exceed five years or extend the total patent term beyond fourteen years from the date of FDA approval.

For a drug-device combination product, the PTE election is a strategic decision. The manufacturer can apply PTE to the CoM patent, a formulation patent, a method patent, or a device patent that recites the API. In most cases, applying PTE to the CoM patent maximizes the protection on the most defensible and hardest-to-design-around claim. But where the CoM patent has a long remaining term and the device patent has a shorter remaining term, applying PTE to the device patent may create a different exclusivity profile — one that protects the specific combination rather than the molecule alone.

EU Regulatory Framework: Supplementary Protection Certificates and Device Combinations

In the European Union, Supplementary Protection Certificates (SPCs) provide patent-like protection for drug products after patent expiration, up to five additional years (plus six months for pediatric medicines). SPCs are product-specific and available only for products that required regulatory authorization under EU drug law.

For drug-device combination products in Europe, the SPC covers the combination as approved, which can include the device component if the combination has a unitary authorization. European SPC case law has grappled with whether SPCs can cover combination products where the device has not itself received separate marketing authorization — a question that has produced conflicting rulings across EU member state courts and that the Court of Justice of the European Union has addressed in several preliminary references.

The European Commission’s pharmaceutical reform package, under negotiation through 2024 and 2025, proposes restructuring the EU regulatory data protection framework significantly. The baseline period would decrease from eight to six years for most drugs, with conditional extensions for unmet medical need, comparative clinical trials, and pan-EU launch. These changes alter the exclusivity architecture for any combination product entering the EU market after the reform takes effect.^[15]

The Connected Device and Software Layer: Patent Strategy for Smart Drug-Delivery Systems

How Digital Health Integration Creates Patentable IP Beyond the Physical Device

The newest layer of drug-device combination patent strategy involves connected devices — inhalers with Bluetooth dose-tracking sensors, autoinjectors with injection-confirmation logging, insulin pumps integrated with smartphone apps and continuous glucose monitor data streams. These products generate patentable innovations across firmware, control software, user interface design, and interoperability standards, in addition to the physical hardware patents that have been the traditional focus of device IP in pharma.

The 2024 European Patent Office medtech report identified over 15,700 medtech patent applications received in 2024, a 1.2% increase from the prior year.^[3] A significant share of the growth in recent filings involves software-implemented innovations in drug delivery systems — dose-tracking algorithms, patient adherence analytics, and closed-loop control logic. These filings are concentrated among pharmaceutical-company-led combination product strategies at AstraZeneca, Novartis, Novo Nordisk, and Sanofi, in addition to specialized medtech companies like Insulet (Omnipod), Tandem Diabetes Care, and Dexcom.

Subject Matter Eligibility for Software-Implemented Drug Delivery Claims: USPTO Section 101 Analysis

Software-implemented claims face eligibility challenges under 35 U.S.C. § 101 following the Supreme Court’s Alice Corp. v. CLS Bank International (2014) decision. Claims covering abstract ideas implemented on a computer must demonstrate that they are directed to “significantly more” than the abstract idea itself. For drug-delivery software, this means the claim must be tied to a specific physical improvement in the drug administration process rather than a general algorithmic concept.

The 2024 USPTO Guidance Update on Subject Matter Eligibility extended the existing framework to AI-assisted drug discovery and combination product software, clarifying that a claim does not become patent-ineligible merely because it was developed using machine learning.^[16] The eligibility analysis turns on whether the claim recites a practical therapeutic application — such as a specific control algorithm for insulin dosing that reduces hypoglycemia events — rather than merely describing a data relationship. Claims tied to specific physical outcomes in drug delivery are generally eligible; claims covering data analytics or monitoring without a physical intervention are more vulnerable.

Closed-Loop Insulin Delivery Patents: Medtronic MiniMed vs. Tandem Control-IQ vs. Insulet Omnipod

The competitive landscape for closed-loop insulin delivery is one of the most patent-intensive spaces in contemporary medtech. Medtronic’s MiniMed patent portfolio covers pump mechanics, infusion set design, and continuous glucose monitor algorithms. Tandem Diabetes Care’s Control-IQ patent estate covers the predictive basal rate algorithm and the hardware integration with Dexcom’s G6 and G7 sensors. Insulet’s Omnipod system carries patents on the tubeless pod design and its wireless communication protocol.

For insulin — the drug itself — the relevant patents are held separately by Eli Lilly (lispro, glargine, degludec) and Novo Nordisk (aspart, detemir). The device companies do not hold drug patents. But the method-of-use patents for specific insulin management regimens using specific device architectures create a zone of IP that partially integrates device and drug by claiming the therapeutic outcome of combining specific insulin delivery parameters with specific control algorithms.

The strategic implication for pharmaceutical companies developing biologic drugs intended for device-integrated administration — including next-generation insulins, subcutaneous biologics, and implantable peptide delivery systems — is that device IP strategy cannot be siloed from drug IP strategy. The therapeutic outcome the combination achieves may itself be patentable, and claims to that outcome can be structured to recite both the drug and the device elements in ways that satisfy the post-Teva v. Amneal API-recitation standard for Orange Book eligibility.

The Loss-of-Exclusivity Timeline: What Combination Patent Portfolios Actually Deliver

Modeling the Exclusivity Horizon for a Drug-Device Combination Product

When a pharmaceutical IP team builds a drug-device combination patent portfolio, the goal is to maximize the gap between CoM patent expiration and effective generic or biosimilar market entry. The gap is created by the layered patent architecture described above, reinforced by regulatory exclusivity periods, complicated by device bioequivalence requirements, and potentially extended by pediatric exclusivity or patent term extension.

A fully executed combination product exclusivity strategy for a small-molecule drug might look like this:

Year 0 (NDA Approval) Primary CoM patent issued. NCE exclusivity begins. Three-year exclusivity for new combination presentation begins if device is new.

Years 1–5 (NCE Exclusivity Period) No ANDA accepted. Formulation patents on the specific drug-device interaction filed. Device platform patents filed covering proprietary delivery mechanism. Claims structured to include API recitation in independent claims.

Years 5–8 (Post-NCE, Pre-First-ANDA-Approval) ANDAs filed with paragraph IV certifications. 30-month stays triggered on Orange Book-eligible combination patents. Litigation begins on formulation and device-integrated patents. Device-only patents enforced separately in parallel federal court actions without 30-month stay benefit.

Years 8–15 (Litigation and Settlement Phase) Combination patent litigation resolves. Settlements set authorized generic entry dates. Method-of-use patents covering device-integrated dosing regimens remain active. Connected device and software patents filed as second-generation platform develops.

Years 15–20 (Long-Tail Device and Method Exclusivity) Device platform patents and method-of-use patents with later priority dates continue to run. Pediatric exclusivity may have added six months. PTE may have extended one key patent. The brand product operates in a protected market segment even after broad generic availability of the base API formulation.

What Happens to Revenue After LOE: Pricing Pressure, Volume Erosion, and Device Premium

Generic entry for a tablet or capsule formulation with no device complexity typically produces 80 to 90 percent volume erosion within 12 months. For a drug-device combination product, the erosion pattern is more variable. Inhalers, autoinjectors, and prefilled syringes require generic manufacturers to demonstrate not only pharmaceutical equivalence but device equivalence — compatible dose delivery, equivalent particle size distribution for inhaled products, equivalent needle gauge and injection force for autoinjectors. This technical complexity slows the generic entry even after patents are cleared.

The AbbVie citrate-free Humira biosimilar transition illustrates the point. Even after all biosimilar entry dates were licensed, patients and prescribers had to be transitioned from high-citrate to citrate-free formulations across both brand and biosimilar versions. The transition generated friction that AbbVie converted to commercial advantage by positioning its citrate-free, low-concentration presentation as superior for patient comfort. Device complexity — in this case the 29-gauge needle and 0.4 ml injection volume — became a marketing asset that supported premium pricing during the initial biosimilar entry period.

Generic Entry Forecast: Which Drug-Device Categories Face Competition Before 2030

Across the combination product landscape, several high-revenue categories face material generic or biosimilar entry before 2030:

• GLP-1 injector pens (semaglutide, liraglutide): Semaglutide NCE exclusivity expired; device patent listings being cleared. First generic liraglutide approved December 2024. Semaglutide generics potentially entering 2025–2026 depending on resolution of remaining patents.
• COPD/asthma combination inhalers (fluticasone/salmeterol, umeclidinium/vilanterol, budesonide/formoterol): Orange Book device patent listings under FTC challenge and delisting pressure. Generic inhalers face bioequivalence complexity but commercially viable generic products for several platforms expected before 2028.
• Adalimumab biosimilars: Already launched in U.S. market since January 2023. Device-citrate-free biosimilar presentations increasing. AbbVie’s device differentiation premium gradually eroding.
• Dupilumab (Dupixent) biosimilars: Primary BPCIA exclusivity runs to approximately 2031. Biosimilar planning underway at multiple companies. Device patents on prefilled syringe and pen presentation will feature in BPCIA patent dance.
• Pembrolizumab (Keytruda) biosimilars: BLA exclusivity and core compound patents run to approximately 2028–2031. IV administration reduces device patent complexity compared to subcutaneous biologics.

Tracking these timelines requires systematic monitoring of both Orange Book listings and BPCIA patent dance disclosures. DrugPatentWatch provides real-time tracking of Orange Book listings, paragraph IV certifications, ANDA filings, patent expiration dates, and patent challenge status across the drug-device combination product landscape, giving IP teams, investors, and competitive intelligence analysts the data foundation for exclusivity modeling.

What This Means for Pharma IP Teams, Generic Strategy Leads, and Investors

For Brand Pharmaceutical IP Teams: The Post-Teva Audit Checklist

Every brand pharmaceutical IP team with drug-device combination products in its portfolio should conduct a systematic audit of Orange Book listings against the Teva v. Amneal standard immediately. The audit has four components:

First, identify every patent listed in the Orange Book for each combination product. Second, review the claims of each listed patent against the API-recitation requirement: does at least one independent claim recite the active ingredient by name or structural definition? Third, for any patent that fails this test, assess the antitrust exposure of maintaining the listing and initiate proactive delisting or claim amendment processes. Fourth, review the pending continuation application portfolio to ensure that any future filings in device patent families include API-reciting claims in at least one independent claim per application.

For existing patents that lack API claims and cannot be reissued without adding new matter, the strategic question is whether they provide value outside the Orange Book context — either as district court enforcement tools against device-copying competitors or as design-around barriers that increase the technical complexity of generic device development. If they do, they should be maintained but no longer listed. If they do not, the maintenance cost versus portfolio cleanup calculus may favor abandonment.

For Generic and Biosimilar Strategy Teams: Identifying Delisting Opportunities

Generic companies approaching drug-device combination products should systematically screen Orange Book listings for device-only patents that fail the API-recitation test. The FTC’s published list of challenged patents, combined with the post-Teva v. Amneal legal standard, provides the analytical framework. Paragraph IV certifications should include delisting counterclaims as a standard component for any Orange Book-listed patent that appears to cover only device components.

Delisting a patent eliminates the 30-month stay risk on that patent alone. In combination product cases with multiple listed patents, strategic delisting can significantly reduce the overall litigation burden by removing device-only patents from the Orange Book while the generic focuses its paragraph IV challenge on the API and method-of-use patents that will require full Hatch-Waxman litigation.

For Institutional Investors: How to Model Exclusivity Risk in Drug-Device Portfolios

The post-Teva v. Amneal regulatory landscape has materially changed the exclusivity risk profile of any branded pharmaceutical product that relies on device-only Orange Book listings for part of its exclusivity architecture. Investment models that valued brand revenue streams based on Orange Book patent expiration dates without distinguishing between API-reciting and device-only patents need to be recalibrated.

The practical question for each position is: of the total Orange Book patent listings for this product, how many recite the API and therefore preserve the 30-month stay protection, and how many are device-only listings that are now subject to delisting or FTC challenge? For any high-revenue inhaler, autoinjector, or injector-pen product, this analysis can shift the effective LOE date by two to five years in either direction relative to a naive reading of the Orange Book expiration schedule.

DrugPatentWatch’s patent tracking infrastructure enables this analysis at scale, providing claim-level visibility into Orange Book listings alongside ANDA filing data, paragraph IV certification records, and litigation outcomes. Systematic use of these tools allows investors to construct exclusivity models that reflect the actual post-Teva v. Amneal legal landscape rather than the pre-2024 assumption that all Orange Book listings carry equivalent Hatch-Waxman protection.

Risk Scenarios: What If the FTC Enforcement Accelerates Further

Scenario A: The FTC Wins Walker Process Claims Against a Major Inhaler Manufacturer

If a federal court awards antitrust damages against a brand manufacturer for improper Orange Book device patent listings — finding that the listing constituted a Walker Process fraud or sham litigation — the consequences go well beyond the specific litigation. A successful antitrust damages award would establish that knowingly listing device-only patents is not merely a regulatory violation requiring delisting but an actionable antitrust offense with treble damages exposure. This would accelerate the self-removal of device-only listings across the industry, as the cost-benefit analysis of maintaining any questionable listing shifts dramatically.

Amneal’s antitrust counterclaims in Teva v. Amneal survived motion to dismiss, which means they will proceed to discovery and potentially trial. The outcome of those counterclaims — expected to produce a ruling or settlement within the next two to three years — will set the damages framework for Walker Process claims based on device patent listings.

Scenario B: The Supreme Court Takes a Device Patent Listing Case and Narrows the Ruling

Teva could petition for certiorari to the Supreme Court in Teva v. Amneal. If the Supreme Court accepts the case and reverses the Federal Circuit — holding that NDA approval of a combination product makes all components of the product eligible for Orange Book listing — the device-only listing landscape reverts to the pre-2024 status quo. Brand manufacturers would relist delisted patents, triggering new stays and potentially new antitrust counterclaims that the reverted standard would undermine.

The probability of Supreme Court reversal is generally considered low by patent law practitioners, given the Federal Circuit’s thorough statutory analysis and the breadth of the policy consensus that supported the outcome. But “low” is not “zero,” and any institution holding branded inhaler or autoinjector revenue streams should track the certiorari petition status.

Scenario C: Congressional Action Defines Combination Product Patent Eligibility by Statute

The policy debate around drug pricing, generic competition, and Orange Book listings has produced legislative proposals at various points over the past decade. If Congress amends 21 U.S.C. § 355 to specify explicitly which types of combination product patents qualify for Orange Book listing — either codifying the Teva v. Amneal standard or altering it — the statutory landscape would supersede both FDA guidance and judicial interpretation. Legislative action could move in either direction: tightening the API-recitation requirement beyond the current Federal Circuit standard, or loosening it to re-permit device-only listings for products where the device provides a genuine clinical benefit.

International Perspectives: Device Patent Strategy Outside the United States

European Patent Strategy for Drug-Device Combinations: Unitary Patent and SPC Interaction

The EU’s Unitary Patent system, which became operational in June 2023, allows pharmaceutical companies to obtain a single patent effective across all EU member states that have ratified the Unified Patent Court (UPC) Agreement. For drug-device combination products, the Unitary Patent offers a materially more efficient enforcement vehicle than the prior national patent system. A single infringement action before the UPC — either in the central division or a local division — can produce a pan-EU injunction or damages award without requiring parallel national proceedings in each member state.

The interaction between Unitary Patents and SPCs for combination products is still being worked out. SPCs are granted by national patent offices based on national patent numbers, but the SPC reform package circulating within EU institutions would create a Unitary SPC tied to the Unitary Patent. For drug-device combination products with pan-EU coverage, the Unitary SPC would provide up to five additional years of pan-EU exclusivity — a significant improvement over the fragmented national SPC system.

Japan and China: Device Patent Strategy in the Asia-Pacific Markets

Japan’s pharmaceutical patent linkage system resembles Hatch-Waxman in structure: Orange Book-equivalent patent listing, generic challenge notification, and litigation stay mechanisms. Japan’s system distinguishes between drug patents and device patents in ways that partially parallel the post-Teva v. Amneal standard, though the specific rules differ from the U.S. framework.

China’s patent linkage system, introduced in 2021 under China’s Drug Administration Law amendments, created an Orange Book-equivalent listing system for patent claims on approved drug products. The system is newer and the body of case law is limited, but device patent listing eligibility is already a contested question in early Chinese pharmaceutical patent litigation. The patent database service PatSnap has identified the 2022–2026 period as a significant filing cohort for implantable drug delivery device patents in Chinese and Japanese jurisdictions, with Merck and Allergan each holding significant China- and Japan-filed portfolios in drug-implant combination strategies.^[6]

India: No Orange Book, but Device Patent Enforcement in the Fastest-Growing Generic Market

India operates no Orange Book equivalent. Generic manufacturers in India can file for approval of generic drug-device combination products without triggering automatic patent stays. Brand pharmaceutical companies seeking exclusivity protection for combination products in India must rely entirely on conventional patent infringement litigation — obtaining injunctions in Indian courts against generic entry on the strength of valid patent claims.

India’s patent law does not permit patents on new forms of known substances unless they demonstrate enhanced efficacy — the Section 3(d) bar. Device patents are generally not subject to this restriction, since they claim physical mechanisms rather than drug forms. A device patent covering a novel autoinjector mechanism, if genuinely novel and non-obvious under Indian patent standards, can be obtained and enforced in India. However, the enforcement timeline in Indian courts makes pre-launch injunctions difficult to obtain, and the practical protection offered by device patents in India is more limited than in the U.S. or EU.

Manufacturing, Supply Chain, and Commercial Implications of Device Patent Strategy

How Device Patents Affect the Generic Device Supply Chain

Generic manufacturers entering the drug-device combination market face a supply chain challenge that goes beyond what a tablet or capsule ANDA requires. They need device components — injector pens, inhalers, prefilled syringes — that do not infringe brand patents on the device mechanism while meeting FDA bioequivalence and device comparability requirements. This demand has created a specialized contract manufacturing market for device components designed to work around specific brand patents.

The contract device manufacturers serving the generic inhaler market — including those supplying metered-dose inhaler valve systems, dry-powder inhaler mechanism components, and prefilled syringe assemblies — operate under patent clearance opinions that verify non-infringement of brand device patents. In the post-Teva v. Amneal world, where device-only Orange Book listings have been cleared for many products, these contract manufacturers face a somewhat different risk landscape. The patents they need to clear are still valid and enforceable; they simply do not trigger automatic stays. The contract manufacturer’s client — the generic drug company — faces potential infringement exposure during the at-risk launch period before device patent litigation concludes.

Device Validation Requirements and the Regulatory Bioequivalence Barrier

FDA’s bioequivalence requirements for inhaled combination products are particularly demanding. For orally inhaled and nasal drug products, FDA requires in vitro characterization of aerodynamic particle size distribution, drug delivery per actuation, drug delivery through patient interface, priming and repriming, dose uniformity testing, and spray pattern analysis. For products with dose counters, the counter must function consistently through the labeled number of actuations. These requirements are specified in product-specific guidances that FDA has developed for major reference inhalers.

This regulatory complexity creates a barrier to generic entry that operates independently of any patent protection. Even a generic manufacturer that clears all relevant patents still faces potentially years of development work to demonstrate that its inhaler device achieves comparable drug delivery performance to the brand product. Device patents during this development phase may be irrelevant commercially — the generic is not close to launch regardless of patent status. But once FDA issues its product-specific guidance and the generic’s device development work matures, the patent landscape becomes the dominant variable in launch timing.

Pricing Premium and Formulary Position: The Commercial Value of a Protected Device Format

Drug-device combination products that maintain exclusivity through device patents — whether through Orange Book-listed API-reciting claims or through the enforcement of device-only claims in district court — can sustain formulary positions and pricing that purely molecule-protected brands cannot. Payers and pharmacy benefit managers typically have less leverage to negotiate formulary rebates for combination products with device complexity because the substitutable generic or biosimilar may not achieve automatic substitution approval due to device equivalence requirements.

This pricing dynamic is particularly relevant in respiratory medicine, where the clinical and regulatory complexity of inhaler equivalence means that generic inhalers for major COPD and asthma products have historically achieved much lower market penetration relative to their tablet and capsule generic counterparts, even years after the first generic approval. Device differentiation — whether protected by active patents or simply by the regulatory inertia of prescriber habit — sustains branded price premiums for longer than the patent timeline alone would predict.

Key Takeaways

Key Takeaways

• Device patents extend branded pharmaceutical exclusivity by a median of 7.5 years for combination products that use them effectively, according to a 2026 JAMA Health Forum study of 331 FDA-approved drug-device products.
• After the Federal Circuit’s December 2024 ruling in Teva v. Amneal, a device patent must include the active pharmaceutical ingredient in at least one independent claim to qualify for Orange Book listing and trigger the 30-month stay. Device-only claims are no longer Orange Book-eligible.
• The FTC has challenged over 300 device patent listings since November 2023 and continued enforcement through May 2025 under both the Biden and Trump administrations. Novo Nordisk delisted all FTC-challenged pen-injector patents for Ozempic, Victoza, and Saxenda.
• Delisting a device patent from the Orange Book does not invalidate the patent. The patent remains enforceable in district court, but the brand loses the automatic 30-month stay protection that makes Hatch-Waxman litigation commercially decisive.
• AbbVie’s 132-patent Humira portfolio, which delayed U.S. biosimilar entry until 2023 and generated an estimated $7.6 billion in excess healthcare costs, demonstrates the commercial ceiling of effective device patent strategy — and the reputational and antitrust risk that comes with pushing it to its limits.
• IP teams must audit all existing Orange Book listings for API-recitation compliance. Any device-only listing that survives the audit should be assessed for antitrust exposure before a generic paragraph IV challenge forces a reactive delisting.
• Future device patent filings for combination products must include API-reciting claims in at least one independent claim. The prosecution workflow for device patent families must be integrated with the pharmaceutical IP team’s API claim drafting practice.
• Connected device and software patents are the newest and fastest-growing layer of drug-device IP. Claims must be structured to meet Section 101 subject matter eligibility standards by tying software innovations to specific physical improvements in drug delivery outcomes.
• In BPCIA proceedings for biosimilar competition, device patents operate without the Orange Book automatic-stay mechanism. Brand companies must seek preliminary injunctions through conventional court proceedings to replicate equivalent competitive protection.
• The $46 billion drug-device combination product market forecast to reach $78 billion by 2030 is the commercial backdrop for all of this IP activity. The companies that build legally defensible, API-reciting combination patent portfolios today will control the revenue protection architecture for the next generation of combination products.

---

FAQ: Drug-Device Combination Patents and Market Exclusivity

1. Can a brand pharmaceutical company still protect a drug-device combination product if its device patents lack API claims?

Yes. Patents without API claims are valid and enforceable. They cannot be listed in the Orange Book and therefore do not trigger the automatic 30-month stay under Hatch-Waxman. The brand manufacturer can still sue for device patent infringement in federal district court, and a generic manufacturer must design around or challenge those patents on the merits. The difference is procedural leverage: without the 30-month stay, the FDA can approve the generic during active litigation, allowing an at-risk launch that changes the commercial math for both sides.

2. What is the difference between an Orange Book listing for a small-molecule drug-device product and Purple Book listing for a biologic drug-device product?

The Orange Book applies to drugs approved under NDAs. The Purple Book applies to biologics approved under BLAs. Orange Book listings trigger Hatch-Waxman patent certification, litigation, and the 30-month stay. Purple Book listings do not carry a stay mechanism — biosimilar patent disputes proceed through the BPCIA patent dance, which can lead to district court litigation but without automatic stay rights. Device patents for biologic combination products therefore cannot be used to generate automatic 30-month stays regardless of whether they recite the API.

3. How does FDA determine whether a product is a combination product and who reviews it?

The FDA’s Office of Combination Products assigns combination products to a lead review center based on the product’s Primary Mode of Action under 21 C.F.R. § 3.2(m). If the drug component provides the most therapeutically important mode of action, CDER leads and the product is approved via NDA. If the device provides it, CDRH leads and the product is approved via 510(k) or PMA. Sponsors can request a formal designation from OCP, and binding designation responses are issued within 60 days of filing a complete Request for Designation.

4. What does the FTC’s challenge to Orange Book patent listings mean for biosimilar and generic manufacturers in practice?

FTC challenges have two practical effects. First, they create reputational and antitrust pressure on brand manufacturers to delist device-only patents voluntarily — as Novo Nordisk, Teva (under court order), and Boehringer Ingelheim have done for challenged products. Second, FTC amicus briefs in litigation, as in Teva v. Amneal, provide federal regulatory weight behind generic manufacturers’ delisting counterclaims, increasing the probability that courts will order delisting over brand manufacturers’ objections. Generic companies should monitor FTC enforcement actions as early signals of Orange Book listings that can be challenged, rather than waiting for litigation to surface the issue.

5. Can a pharmaceutical company use reissue proceedings to add API-reciting claims to an existing device patent?

Potentially, yes. Under 35 U.S.C. § 251, a patent can be reissued to correct errors, add narrower claims, or in some cases broaden claims within two years of issuance. Whether adding API-reciting claims to an existing device patent constitutes adding “new matter” depends on the original specification’s disclosure. If the original specification describes the device in the context of a specific API — which is common for device patents filed as part of a pharmaceutical product development program — then adding claims that recite the API explicitly may be permissible as drawing on already-disclosed subject matter. This is fact-specific and requires analysis by patent counsel.

6. How does the loss of Orange Book-listed device patents affect a drug’s financial model in market exclusivity analysis?

The financial impact depends on whether the device-only patents were the last listed Orange Book patents before generic entry — in which case their delisting can accelerate generic ANDA approval by years — or whether they were one layer in a stack that includes API and method-of-use patents with later expiration dates. For many products, the device-only listings were providing 30-month stay protection during ANDA litigation even if underlying API patents would ultimately have governed the exclusivity timeline. Analysts should remodel exclusivity horizons by removing device-only listings from the protective patent count and reassessing when the first fully unconstrained generic ANDA approval becomes possible.

7. What patent strategy should a pharmaceutical company use for a new subcutaneous formulation of an existing IV biologic?

A subcutaneous presentation of an existing IV biologic creates a fresh combination patent opportunity. The IP strategy should include: formulation patents on the specific subcutaneous formulation (drug concentration, excipients, pH, viscosity); device patents on the delivery system (prefilled syringe, autoinjector, or on-body injector) with API-reciting independent claims; method-of-treatment patents covering the subcutaneous administration regimen, titration protocol, and any patient selection criteria unique to the subcutaneous route; and potentially a co-formulation patent if the subcutaneous presentation requires hyaluronidase or another excipient. FDA 3-year exclusivity may be available if new clinical investigations were conducted to support the subcutaneous NDA or BLA supplement.

8. What competitive intelligence tools track drug-device combination patent filings, Orange Book listings, and paragraph IV certifications?

DrugPatentWatch provides real-time data on Orange Book listings, patent expiration dates, paragraph IV certifications, ANDA filing activity, and litigation outcomes for drug-device combination products. It enables IP teams and investors to screen Orange Book listings against API-recitation criteria, track FTC-challenged patents, and model exclusivity horizons for specific products. PatSnap provides global patent filings data including device patent families. The FDA’s Orange Book database is publicly searchable, and the FDA Orange Book Patent Dispute process — under which companies like Novo Nordisk voluntarily delisted patents — is tracked through FDA’s published dispute records.

9. Does the Teva v. Amneal ruling apply to prefilled syringe and autoinjector device patents the same way it applies to inhaler device patents?

Yes. The Federal Circuit’s ruling is based on statutory interpretation of 21 U.S.C. § 355(b)(1)(A)(viii), which governs all NDA-approved drug products — not just inhalers. The requirement that an Orange Book-listed patent must claim the drug (including its active ingredient) applies equally to autoinjector, prefilled syringe, subcutaneous injector, and any other drug-device combination product approved via NDA. The FTC’s enforcement campaign has explicitly targeted autoinjector patents for epinephrine, GLP-1 injector pens, and other non-inhaler combination products. The ruling’s scope is broad.

10. How does AbbVie’s Humira device patent strategy compare to what would be permissible under the post-2024 legal standard?

AbbVie’s Humira device patents were part of a biosimilar patent thicket enforced under the BPCIA framework, not the Orange Book/Hatch-Waxman system, because adalimumab is a biologic approved under a BLA. The Teva v. Amneal ruling and Orange Book listing requirements do not directly apply to BPCIA patents. However, the principle carries over: a device patent that is asserted in BPCIA litigation and does not recite the active ingredient is less defensively robust in the patent dance because it has weaker claims to therapeutic relevance. In the small-molecule Orange Book context, the specific autoinjector-pen patents that AbbVie filed for Humira’s citrate-free, high-concentration formulation would need to recite adalimumab or a functional equivalent of it in at least one independent claim to qualify for Orange Book listing under the current standard.

---

Sources

1. DrugPatentWatch. (2026, April 8). Drug-device combination product patents: The strategic playbook for turning regulatory complexity into market lock-in. DrugPatentWatch. https://www.drugpatentwatch.com/blog/patents-combination-products-challenges-opportunities/
2. U.S. Food and Drug Administration. (2005, August 25). Definition of primary mode of action of a combination product. Federal Register, 70(164), 49848–49862. https://www.federalregister.gov/documents/2005/08/25/05-16527/definition-of-primary-mode-of-action-of-a-combination-product
3. Teng, T. W., et al. (2026). Tertiary patents on drugs approved by the FDA. JAMA Health Forum. https://pmc.ncbi.nlm.nih.gov/articles/PMC12761334/
4. DrugPatentWatch. (2026, February 8). The evergreening playbook: How pharma extends drug exclusivity — and what it actually costs. DrugPatentWatch. https://www.drugpatentwatch.com/blog/the-evergreening-playbook-how-pharma-extends-drug-exclusivity-and-what-it-actually-costs/
5. Pharmaceutical Technology. (2025, August 8). EpiPen patent expiry opens new era for innovation. https://www.pharmaceutical-technology.com/news/epipen-patent-expiry-opens-new-era-for-innovation/
6. FiercePharma. (2024, May 1). FTC targets Novo’s Ozempic, others in crackdown on 300-plus ‘junk’ patent listings in FDA database. https://www.fiercepharma.com/pharma/ftc-targets-novos-ozempic-others-crackdown-300-plus-junk-patent-listings-fda-database
7. The Capitol Forum. (2025, March 25). Teva: Drugmaker requests delisting of inhaler patents from Orange Book; Boehringer Ingelheim, Novo Nordisk have also asked FDA to pull disputed drug-device patents. https://thecapitolforum.com/teva-inhaler-patents-orange-book/
8. Patently-O. (2024, December 20). Orange Book device patent listings: Understanding Teva v. Amneal. https://patentlyo.com/patent/2024/12/orange-listings-understanding.html
9. Cooley LLP. (2025, January 2). Teva v. Amneal ruling interprets Orange Book listing statute, affirms delisting of device patents. https://www.cooley.com/news/insight/2025/2025-01-02-teva-v-amneal-ruling-interprets-orange-book-listing-statute-affirms-delisting-of-device-patents
10. DrugPatentWatch. (2025, December 4). The uncoupling of device and drug: A strategic post-mortem of Teva v. Amneal and the new era of Orange Book rigor. DrugPatentWatch. https://www.drugpatentwatch.com/blog/the-uncoupling-of-device-and-drug-a-strategic-post-mortem-of-teva-v-amneal-and-the-new-era-of-orange-book-rigor/
11. Hogan Lovells. (2025). Republican FTC renews challenges to Orange Book patent listings. https://www.hoganlovells.com/en/publications/republican-ftc-renews-challenges-to-orange-book-patent-listings
12. Edgeworth Economics. (2024, August 21). An antitrust economist’s perspective on recent FTC scrutiny towards Orange Book patent listing. https://www.edgewortheconomics.com/publication-FTC-orange-book
13. Haaretz/Finnegan. (2025, May 27). Strategies for effectively enhancing IP value of critical assets after Teva v. Amneal and other recent decisions. https://www.haaretz.com/haaretz-labels/2025-05-27/ty-article-labels/strategies-for-effectively-enhancing-ip-value-of-critical-assets-after-teva-v-amneal
14. DrugPatentWatch. (2026, March 22). Drug patent strategy: The definitive guide for pharmaceutical IP teams, R&D leads, and institutional investors. DrugPatentWatch. https://www.drugpatentwatch.com/blog/optimizing-your-drug-patent-strategy-a-comprehensive-guide-for-pharmaceutical-companies/
15. DrugPatentWatch. (2026, March 10). The patent cliff playbook: Pharmaceutical IP valuation, generic entry timing, and biosimilar strategy. DrugPatentWatch. https://www.drugpatentwatch.com/blog/patent-expirations-seizing-opportunities-in-the-generic-drug-market/
16. DrugPatentWatch. (2026, March 23). A strategic guide to patenting drug combinations. DrugPatentWatch. https://www.drugpatentwatch.com/blog/successfully-patenting-drug-combinations-strategies-and-challenges/
17. IntuitionLabs. (2026, May). Drug patents expiring in 2026: A comprehensive guide. https://intuitionlabs.ai/articles/drug-patent-expirations-2026
18. Life Science Leader. (2025). Navigating the GLP-1 litigation landscape. https://www.lifescienceleader.com/doc/navigating-the-glp-litigation-landscape-0001
19. Avorn, J., et al. (2025). Serial patent litigation: An emerging strategy to delay entry of generic competition. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12757684/
20. DrugPatentWatch. (n.d.). When will the DUPIXENT patents expire, and when will biosimilar DUPIXENT be available? https://www.drugpatentwatch.com/p/biologics/tradename/DUPIXENT

Copyright © DrugPatentWatch. Originally published at